Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $18.0 million.

  • Cumberland Pharmaceuticals' Cash & Equivalents fell 12.99% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 12.99%. This contributed to the annual value of $18.0 million for FY2024, which is 1.95% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Cash & Equivalents stood at $18.0 million for FY2024, which was down 1.95% from $18.3 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Cash & Equivalents peaked at $27.0 million during FY2021, and registered a low of $18.0 million during FY2024.
  • Its 3-year average for Cash & Equivalents is $18.7 million, with a median of $18.3 million in 2023.
  • In the last 5 years, Cumberland Pharmaceuticals' Cash & Equivalents grew by 9.24% in 2021 and then fell by 26.93% in 2022.
  • Cumberland Pharmaceuticals' Cash & Equivalents (Yearly) stood at $24.8 million in 2020, then rose by 9.24% to $27.0 million in 2021, then dropped by 26.93% to $19.8 million in 2022, then decreased by 7.27% to $18.3 million in 2023, then decreased by 1.95% to $18.0 million in 2024.